摘要
现阶段对于"瓣膜病变型"房颤(AF)与"非瓣膜病变型"AF的定义尚未达成共识,不仅如此,各指南在表述这些概念时也存在差异。临床试验对于"瓣膜病变型"AF与"非瓣膜病变型"AF定义的阐述不甚理想。两类AF血栓栓塞风险差异较大,抗凝治疗策略也有所不同。本文将对瓣膜性AF定义及抗凝治疗的研究进展予以综述。
There is no consensus on the definition of “valvular disease” atrial fibrillation and “non valvular disease” atrial fibrillation and there are also different explanations in these concepts provided by different guidebooks. The definitions of “valvular disease” and “non valvular disease” from clinical trials are not ideal. In fact, the two types of atrial fibrillations are very different in their risk of thromboembolism and so are their anticoagulant treatment strategies. This article will review the definition of valvular atrial fibrillation and its progress in anticoagulation therapy.
出处
《心脏杂志》
CAS
2017年第5期610-613,共4页
Chinese Heart Journal
基金
国家自然科学基金项目资助(81470479)
陕西省社会发展科技攻关项目资助(2014K11-03-01-04
2014K12-07)
关键词
心房颤动
非瓣膜性房颤
瓣膜性房颤
血栓栓塞
新型口服抗凝药物
atrial fibrillation
non-valvular atrial fibrillation
valvular atrial fibrillation
thrombo-embolic
non-VKA oral anticoagulants
